FDA's Off-Label Delay Not Enough For Big Drugmakers

By Jeff Overley (February 7, 2018, 8:26 PM EST) -- The U.S. Food and Drug Administration's delay of controversial new policies on off-label promotion doesn't go far enough and should be followed by quick action to erase uncertainty about acceptable marketing practices, major drugmakers said in letters released late Tuesday.

The letters, posted after a comment deadline this week, relate to the FDA's move last month to indefinitely delay a final rule with new off-label policies. The policies outlined how regulators will assess the "intended use" of drugs and devices — including whether products are intentionally being promoted for unapproved uses.

The controversy centers on the FDA's plan to examine "the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!